Amneal Pharmaceuticals
AMRX
317 hedge funds and large institutions have $2B invested in Amneal Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 80 funds opening new positions, 115 increasing their positions, 78 reducing their positions, and 36 closing their positions.
122% more first-time investments, than exits
New positions opened: 80 | Existing positions closed: 36
47% more repeat investments, than reductions
Existing positions increased: 115 | Existing positions reduced: 78
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
14% more funds holding
Funds holding: 277 → 317 (+40)
1.28% more ownership
Funds ownership: 49.16% → 50.44% (+1.3%)
3% more capital invested
Capital invested by funds: $1.95B → $2B (+$52.7M)
56% less call options, than puts
Call options by funds: $635K | Put options by funds: $1.44M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$137M |
| 2 |
State Street
Boston,
Massachusetts
|
+$36M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$19.3M |
| 4 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$14.4M |
| 5 |
Principal Financial Group
Des Moines,
Iowa
|
+$11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$75.2M |
| 2 |
Millennium Management
New York
|
-$40.2M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$17.4M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$17.1M |
| 5 |
JG
Jain Global
New York
|
-$13.4M |
AMRX Hedge Fund Activity: Q1 2026 in Review
317 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q1 2026, worth a combined $2B — up 2.7% from $1.95B a quarter earlier.
Buyers outnumbered sellers: 80 funds opened new AMRX positions and 36 closed out — a net gain of 44 holders — while 115 added to existing stakes and 78 trimmed.
The largest buyer was BlackRock, adding an estimated $137M. The largest seller was Citadel Advisors, cutting an estimated $75.2M.
- 317 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q1 2026, up from 277 in Q4 2025.
- Funds reported $2B of Amneal Pharmaceuticals stock for Q1 2026, up 2.7% quarter-over-quarter.
- 80 funds opened new Amneal Pharmaceuticals positions in Q1 2026 and 36 closed out, a net change of +44 holders.
- The largest Amneal Pharmaceuticals buyer in Q1 2026 was BlackRock, an estimated $137M added.
- The largest Amneal Pharmaceuticals seller in Q1 2026 was Citadel Advisors, an estimated $75.2M sold.
Based on aggregated 13F filings for Q1 2026.